87 related articles for article (PubMed ID: 21922393)
1. Individualization of treatment strategies.
Fernández Ortega A; Jolis López L; Viñas Villaró G; Villanueva Vázquez R; García Arias A; González Farré X; González Jiménez S; Saura Manich C; Cortés Castán J
Adv Ther; 2011 Sep; 28 Suppl 6():19-38. PubMed ID: 21922393
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant hormonal therapy in perimenopausal patients.
Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
[TBL] [Abstract][Full Text] [Related]
3. Update on adjuvant hormonal treatment of early breast cancer.
Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
[TBL] [Abstract][Full Text] [Related]
4. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
5. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Dickler M
Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
[No Abstract] [Full Text] [Related]
6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
Puhalla S; Jankowitz RC; Davidson NE
J Natl Cancer Inst; 2011 Sep; 103(17):1280-2. PubMed ID: 21859987
[No Abstract] [Full Text] [Related]
10. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
11. Concurrent versus sequential radiotherapy and tamoxifen in breast cancer - The CONSET trial is launched.
Munshi A; Gupta D
Acta Oncol; 2011 Jan; 50(1):154-5. PubMed ID: 20843175
[No Abstract] [Full Text] [Related]
12. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
13. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
14. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
Hayward RL; Dixon JM
Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of adjuvant endocrine therapy for postoperative breast cancer patients].
Doihara H; Ogasawara Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():563-7. PubMed ID: 17682212
[No Abstract] [Full Text] [Related]
16. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Alliot C
J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
[No Abstract] [Full Text] [Related]
17. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Gligorov J; Pritchard K; Goss P
Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
20. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]